

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

(1) POLL RESULTS OF THE THIRD EGM HELD ON DECEMBER 23, 2022
(2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION

Reference is made to the circular (the “**Circular**”) and the notice (the “**Notice**”, together with the Circular, the “**EGM Documents**”) of the third extraordinary general meeting (the “**Third EGM**”) of Jenscare Scientific Co., Ltd. (the “**Company**”) both dated December 7, 2022. Unless the context otherwise requires, the terms used in this announcement shall have the same meaning as those defined in the EGM Documents.

The Board is pleased to announce that the Third EGM was convened and held on Friday, December 23, 2022 at Meeting Room, 3/F, Block 5, B Area, No. 777 Binhai 4th Road, Hangzhou Bay New Area, Ningbo, Zhejiang Province, PRC.

As at the date of the Third EGM, the total number of Shares in issue was 417,167,290 Shares, comprising 131,590,632 H Shares and 285,576,658 Unlisted Shares, which was the total number of Shares entitling holders to attend and vote on the proposed resolutions at the Third EGM. Shareholders holding a total of 370,525,198 Shares and representing approximately 88.82% of the total number of issued Shares (including their proxies and authorised representatives) attended the Third EGM. All the proposed resolutions as set out in the Notice were voted by way of poll at the Third EGM.

For resolutions (2) and (3), each of Mr. LV Shiwen, Ningbo Sangdi Investment Management L.P. (Limited Partnership) (寧波桑迪投資管理合夥企業(有限合夥)) (“**Ningbo Sangdi**”), Ningbo Mukang Venture Capital Partnership (Limited Partnership) (寧波沐康創業投資合夥企業(有限合夥)) (“**Ningbo Mukang**”), Ningbo Kefeng Investment Management L.P. (Limited Partnership) (寧波鈞豐投資管理合夥企業(有限合夥)) (“**Ningbo Kefeng**”), Hainan Maidu Enterprise Management L.P. (Limited Partnership) (海南脈迪企業管理合夥企業(有限合夥)) (“**Hainan Maidu**”), Shanghai Shidi Industrial Development Co., Ltd. (上海仕地實業發展有限公司) (“**Shanghai Shidi**”), Ningbo Linfeng Biotechnology Co., Ltd. (寧波麟豐生物科技有限有限公司) (“**Ningbo Linfeng**”) and Hainan Hualing Investment L.P. (Limited Partnership) (海南華翎投資合夥企業(有限合夥)) (“**Hainan Hualing**”) were required to abstain from voting.

Save as disclosed from above, (i) there were no Shares entitling the Shareholders to attend and abstain from voting in favour of the resolutions proposed at the Third EGM pursuant to Rule 13.40 of the Listing Rules; (ii) none of the Shareholders were required under the Listing Rules to abstain from voting at the Third EGM; and (iii) none of the Shareholders had stated their intention in the Circular to vote against or to abstain from voting on the resolutions proposed at the Third EGM.

The Third EGM was legally and validly convened in accordance with the provisions of the Company Law of the People's Republic of China and the Articles of Association.

Computershare Hong Kong Investor Services Limited, being the Company's H share registrar in Hong Kong, was appointed as the scrutineer for the purpose of vote-taking at the EGM. Two representatives of the Shareholders, one lawyer of Commerce & Finance Law Offices and one supervisor of the Company participated in the scrutiny of the poll results.

POLL RESULTS OF THE EGM

The Third EGM was convened by the Board. Mr. LV Shiwen, the chairman and executive Director, was the chairman of the EGM and presided over the Third EGM.

All Directors attended the Third EGM either in person or by electronic means.

The poll results in respect of the proposed resolutions at the Third EGM were as follows:

Special Resolution		Number of votes (approximate percentage)		
		For	Against	Abstain
1.	To consider and approve the proposed amendments to the articles of association of the Company.	370,525,198 (100%)	0 (0%)	0 (0%)
Ordinary Resolutions		Number of votes (approximate percentage)		
		For	Against	Abstain
2.	To consider and approve the proposed adjustments to the employee incentive plans of the Company.	166,315,612 (100%)	0 (0%)	0 (0%)
3.	To consider and approve the authorization to the board to of directors of the Company to handle matters related to the employee incentive plans of the Company.	166,315,612 (100%)	0 (0%)	0 (0%)

In respect of the above special resolution numbered 1, as more than two-third of the voting rights represented by the Shareholders (including their proxies) attending the Third EGM were cast in favour of such resolution, such resolution was duly passed as special resolution at the Third EGM.

In respect of the above ordinary resolutions numbered 2 and 3, as more than one-half of the voting rights represented by the Shareholders (including their proxies) attending the Third EGM (excluding Mr. LV Shiwen, Ningbo Sangdi, Ningbo Mukang, Ningbo Kefeng, Hainan Maidi, Shanghai Shidi, Ningbo Linfeng and Hainan Hualing) were cast in favour of all such resolutions, all such resolutions were duly passed as ordinary resolutions at the Third EGM.

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

The Proposed Amendments have been approved by the Shareholders by way of a special resolution at the Third EGM and has become effective on December 23, 2022. The full text of the amended Articles of Association will be published on the websites of the Stock Exchange and the Company.

By order of the Board
Jenscare Scientific Co., Ltd.
LV Shiwen
Chairman and Executive Director

Hong Kong, December 23, 2022

As at the date of this announcement, the executive directors of the Company are Mr. LV Shiwen and Mr. PAN Fei; the non-executive directors are Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.